Why Shares of Zentalis Pharmaceuticals Dropped This Week
Shares of Zentalis Pharmaceuticals (NASDAQ: ZNTL) were down 13.5% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence. The stock's prices were likely driven down by lowered investor sentiment due to a rash of insider selling. Zentalis is a clinical-stage biotech company that focuses on small-molecule therapies to treat cancer, specifically cancers with broad patient populations.